Evidence map›Paper›PMID 36373485›Full record

ArticleEmerging microbes & infections2023

Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort.

Liguo Zhu, Naiying Mao, Changhua Yi, Aidibai Simayi, Jialu Feng, Yi Feng, Min He, Songning Ding, Yin Wang, Yan Wang and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Liguo ZhuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Naiying MaoNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Changhua YiNanjing Infectious Diseases Clinical Medical Center (The Second Hospital of Nanjing, Nanjing University of Chinese Medicine), Nanjing, P.R China.
Aidibai SimayiDepartment of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, China.ORCID 0000-0003-3916-8030
Jialu FengSchool of Public Health, Nanjing Medical University, Nanjing, People's Republic of China.
Yi FengNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Min HeNanjing Municipal Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Songning DingNanjing Municipal Center for Disease Control and Prevention, Nanjing, People's Republic of China.
Yin WangYangzhou Center for Disease Control and Prevention, Yangzhou, Pople's Republic of China.
Yan WangYangzhou Center for Disease Control and Prevention, Yangzhou, Pople's Republic of China.
Mingwei WeiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Jie HongNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Chuchu LiNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Hua TianNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Lu ZhouNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Jiefu PengNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Shihan ZhangDepartment of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, China.
Ci SongSchool of Public Health, Nanjing Medical University, Nanjing, People's Republic of China.
Hui JinDepartment of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing, China.
Fengcai ZhuNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.ORCID 0000-0002-1644-0006
Wenbo XuNational Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Jun ZhaoThe Third People's Hospital of Yangzhou, Yangzhou, People's Republic of China.
Changjun BaoNHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.
Jiangsu Provincial Center for Disease Control and Prevention · CNChinese Center For Disease Control and Prevention · CNSoutheast University · BDNanjing Medical University · CNNanjing Municipal Center for Disease Control And Prevention · CNNanjing University of Chinese Medicine · CNPeople's Hospital of Yangzhong · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

How much the vaccine contributes to the induction and development of neutralizing antibodies (NAbs) of breakthrough cases relative to those unvaccinated-infected cases is not fully understood. We conducted a prospective cohort study and collected serum samples from 576 individuals who were diagnosed with SARS-CoV-2 Delta strain infection, including 245 breakthrough cases and 331 unvaccinated-infected cases. NAbs were analysed by live virus microneutralization test and transformation of NAb titre. NAbs titres against SARS-CoV-2 ancestral and Delta variant in breakthrough cases were 7.8-fold and 4.0-fold higher than in unvaccinated-infected cases, respectively. NAbs titres in breakthrough cases peaked at the second week after onset/infection. However, the NAbs titres in the unvaccinated-infected cases reached their highest levels during the third week. Compared to those with higher levels of NAbs, those with lower levels of NAbs had no difference in viral clearance duration time (

Indexed as

COVID-19SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralHumansNeutralization TestsProspective StudiesVaccinationAntibodies, NeutralizingAntibodies, Viralbreakthrough infectionCoronaVacDelta variantneutralizing antibodySARS-CoV-2

Identifiers

PMID36373485
PMCPMC9858416
OpenAlexW4308956724

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.